Ionis Pharmaceuticals News and Activities

Ionis Pharmaceuticals is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Ionis Pharmaceuticals is a company listed under the stock ticker IONS (US).

View the org chart displaying its 23 main executives

Most searched biographies at Ionis Pharmaceuticals

• Brett Monia, Chief Executive Officer and Director
• Joseph Loscalzo, Chairman of The Board
• Peter Reikes, Director

Popular executive movements at Ionis Pharmaceuticals

• Joseph Wender, Director, will retire on Jun. 4, 2026  (posted on March 9 2026).
• Peter Reikes will join the company as Director on Jun. 4, 2026  (posted on March 9 2026).
• Lynne Parshall, Director, will retire on Jun. 4, 2026  (posted on March 9 2026).

Create your alert
to follow the executive moves at Ionis Pharmaceuticals.

Ionis Pharmaceuticals has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Ionis Pharmaceuticals

• Ionis reports third quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
• Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
• Ionis to present at upcoming investor conferences | Ionis Pharmaceuticals, Inc.
• Ionis reports second quarter 2023 financial results | Ionis Pharmaceuticals, Inc.
• Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy | Ionis Pharmaceuticals, Inc.
• Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease | Ionis Pharmaceuticals, Inc.
• Ionis to hold second quarter 2023 financial results webcast | Ionis Pharmaceuticals, Inc.
• Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America | Ionis Pharmaceuticals, Inc.
• Eplontersen continued to show improvement in ATTRv-PN through 85 weeks | Ionis Pharmaceuticals, Inc.
• Ionis to present at upcoming investor conference | Ionis Pharmaceuticals, Inc.
• View more press releases Close

Social media about Ionis Pharmaceuticals

• Ionis Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Ionis Pharmaceuticals on LinkedIn, X (Twitter) & YouTube